Thus, the pressure overload-induced pathologic cardiac hypertrophy on account of TRAF5 deficiency is most likely a result of the activation of ERK1/2-dependent NF-κB and MEK-ERK1/2 signaling. Here, MAPK3 is linked to cardiac hypertrophy.